Clinical trials: Enteric Fever
Iron Deficiency Anemia
Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity
Iron deficiency (ID) anaemia (IDA) is a global public health problem, with the highest prevalence in Africa and in South-East Asia.
- Trial name
- NCT06027801
- Testing
- Iron-fortified cookies, Japanese encephalitis (JE) vaccine, Typhoid Vi polysaccharide (Vi-PS) vaccine
- Where
- Thailand
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Salmonella Infections, Infection of Bloodstream
Reservoir of Invasive Salmonellosis in Children, DRC
Bloodstream infections caused by non-typhoid Salmonella (NTS) are a major killing disease in Sub-Saharan Africa. Despite the high case fatality rate, the main reservoir -human, zoonotic or environmental- for invasive NTS rests…
- Trial name
- NCT03073707
- Testing
- Sample collection
- Where
- Democratic Republic of the Congo
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Hepatitis A
Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity
To evaluate the immunogenicity, reactogenicity and safety of Hepatyrix when compared to the concomitant administration of Typherix and Havrix, and when compared to the administration of monovalent vaccines, Havrix or Typhim Vi.
- Trial name
- NCT00197249
- Testing
- Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix
- Volunteers
- 1,034 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Typhoid, Cholera
Co-administration Study of OCV, TCV and MR
An open-label, randomized controlled, non-inferiority study of co-administration of OCV, TCV and MR vaccines among children 12 to 59 months of age in Dhaka, Bangladesh will be conducted.
- Conditions
- Typhoid, Cholera, Measles, Rubella
- Trial name
- NCT05771779
- Testing
- Oral Cholera Vaccine (OCV), Typhoid Conjugate Vaccine (TCV), Measles and Rubella (MR)
- Volunteers
- 2,117 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Intestinal Permeability, Inflammation
Induction of Gut Permeability by an Oral Vaccine
This study evaluates the effect of an oral typhoid vaccine on disruption of the intestinal barrier and response of the immune system.
- Conditions
- Intestinal Permeability, Inflammation, Vaccine, Typhoid Fever
- Trial name
- NCT04083950
- Testing
- Vivotif Typhoid Oral Vaccine, Aspirin (Positive Control)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- USDA, Western Human Nutrition Research Center
Salmonella Infections
A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants
The purpose of this study is to evaluate the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid…
- Trial name
- NCT07286370
- Testing
- Low dose of iNTS-TCV, Full dose of iNTS-TCV, TYPHIBEV
- Where
- The Gambia
- Volunteers
- 537 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Risk Reduction
Blood Donor CVD 5000
This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries.
- Trial name
- NCT03971669
- Testing
- Vivotif Typhoid Oral Vaccine
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Salmonella Infections, Salmonella Typhimurium
Challenge Non-Typhoidal Salmonella (CHANTS) Study
This protocol describes the challenge non-typhoidal Salmonella (CHANTS) study. This is a first-in-human phase 1, double-blinded, randomised, dose-escalation human infection study, conducted in healthy volunteers aged 18 to 50…
- Conditions
- Salmonella Infections, Salmonella Typhimurium, Non-typhoidal Salmonella (NTS), Invasive Non-Typhoidal Salmonella Disease
- Trial name
- CHANTS (NCT05870150)
- Testing
- Salmonella Typhimurium
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust
Typhoid
Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine
This is a randomized, observer-blinded Phase 2 study in healthy infants and toddlers 6-23 months of age at the time of the first vaccine dose.
- Trial name
- NCT03527355
- Testing
- Vi-DT, FluQuadri™, 0.9% sodium chloride isotonic solution
- Where
- Philippines
- Volunteers
- 285 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid Fever
Safety and Immunogenicity of Typhax, a Typhoid Vaccine
This was a randomized, double-blind, ascending dose study conducted at a single clinical research center.
- Trial name
- NCT03926455
- Testing
- Typhax (investigational typhoid fever candidate vaccine), Active Comparator Typhim Vi
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Matrivax Research and Development Corporation
Influenza, Hepatitis A
Effects of Aging on Primary and Secondary Vaccine Responses
The purpose of this study is to use an existing, unique clinical cohort: the longitudinal cohort of younger (21-40 years) and elderly (>65 years) subjects whose yearly influenza vaccine responses have been studied extensively…
- Conditions
- Influenza, Hepatitis A, Typhoid, Healthy Adults
- Trial name
- SLVP033 (NCT03312699)
- Testing
- Fluzone® quadrivalent, Fluzone High Dose, Fluad
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Stanford University
Healthy
Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines
In a recent controlled study, the investigators explored cross-reactive immune responses against different Salmonella spp. in healthy volunteers immunized with either the oral (Vivotif® ) or parenteral (Typherix®) typhoid…
- Trial name
- Ty21a-ASC (NCT02121145)
- Testing
- Vivotif, Typherix
- Where
- 3 sites in Finland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Typhoid and Paratyphoid Fevers
TY800 Dose Escalation (Typhoid)
The purpose of this research study is to determine whether a new vaccine for typhoid fever is safe and effective. This study will also look at what effects (good and bad) this new vaccine, Ty800, has on the volunteers.
- Trial name
- NCT00269295
- Testing
- Ty800
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Salmonella Infections
A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever
The purpose of this study is to assess the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid…
- Trial name
- NCT05480800
- Testing
- Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose, Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose, Typhoid conjugate vaccine (TCV) low dose
- Where
- 2 sites in Belgium, Malawi
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Typhoid Fever, Paratyphoid Fever
Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge Study
Enteric fever, an infection characterised by diarrhoea and rash, is most often caused by a bacteria called Salmonella enterica. After ingesting contaminated food or drink, the Salmonellae travel first to the gut, then the…
- Trial name
- NCT02192008
- Testing
- Salmonella Typhi, Salmonella Paratyphi
- Where
- United Kingdom
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Typhoid
Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi
This study will evaluate the efficacy of a Typhoid conjugate vaccine (Vi-TCV) in Malawi, Africa among children age 9 months through 12 years.
- Trial name
- NCT03299426
- Testing
- Vi-Typhoid Conjugate Vaccine (Vi-TCV), Meningococcal A Conjugate Vaccine (MCV-A)
- Where
- Malawi
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Typhoid Fever
Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults
The purpose of this study is to evaluate the immunogenicity and the kinetics of the anti-Vi antibody response following secondary vaccination with the Novartis Vaccines Institute for Global Health (NVGH) Vi-CRM197 vaccine in…
- Trial name
- NCT01438996
- Testing
- NVGH Vi-CRM197
- Where
- Belgium
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Novartis
Typhoid Fever
Diagnosis and Staging of Typhoid Fever Using Surface-enhanced Raman Spectroscopy Liquid Biopsy
The goal of this project is to adapt the gold nanoparticle-based surface-enhanced Raman spectroscopy (SERS) technology to clinical application.
- Trial name
- NCT06546982
- Testing
- Surface-enhanced Raman Spectroscopy
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Aachen
Vaccine
Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian
Vi-DT Typhoid vaccine is a novel vaccine. This study will be done to know the long-term protection and persistent antibody by measured the antibody titer after 2,3,4 and 5 years after immunization.
- Trial name
- NCT04741828
- Testing
- Vi-DT Typhoid Conjugate Vaccine
- Where
- 2 sites in Indonesia
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Typhoid Fever
CVD 909 Vi Prime Boost Study
The purpose of this research study is to see if giving a typhoid vaccine by mouth (an experimental vaccine, CVD 909) before giving a vaccine shot (Typhim Vi) will result in a better immune response than giving Typhim Vi vaccine…
- Trial name
- NCT00326443
- Testing
- CVD 909, Vi Polysaccharide
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)